Aspirin Reduces the Incidence of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Receiving Oral Nucleos(t)ide Analog

Vicki Wing-Ki Hui, BSc1,2,3, Terry Cheuk-Fung Yip, PhD1,2,3, Vincent Wai-Sun Wong, MD1,2,3, Yee-Kit Tse, MPhil1,2,3, Henry Lik-Yuen Chan, MD1,2,3, Grace Chung-Yan Lui, MD1,2,4 and Grace Lai-Hung Wong, MD1,2,3

INTRODUCTION: Aspirin may reduce the risk of chronic hepatitis B (CHB)-related hepatocellular carcinoma (HCC) in patients receiving antiviral treatment. We aimed to investigate the impact of aspirin on reducing HCC risk in patients treated with first-line oral nucleos(t)ide analogs (NAs; entecavir and/or tenofovir disoproxil fumarate).

METHODS: We conducted a territorywide, retrospective cohort study in NA-treated CHB patients between 2000 and 2018 from the electronic healthcare data repository in Hong Kong. Subjects were classified into aspirin users for at least 90 days during NA treatment (aspirin group) or no aspirin or any other antiplatelet use during follow-up period (no aspirin group). Incidence rates of HCC and gastrointestinal bleeding (GIB) in 2 groups with propensity score matching with 1:3 ratio.

RESULTS: Of 35,111 NA-treated CHB patients of mean age of 53.0 years and 61.6% men, sixty-nine (4.0%) and 1,488 (4.5%) developed HCC at a median (interquartile range) of 2.7 (1.4–4.8) years and 3.2 (1.8–6.0) years in the aspirin group and no aspirin group, respectively. A duration-dependent association between aspirin and the risk of HCC was observed (subhazard ratio [sHR] 3 months–2 years: 0.65; 95% confidence interval [CI] 0.47–0.92; sHR 2–5 years: 0.63; 95% CI 0.43–0.94; sHR from ≥5 years: 0.41; 95% CI 0.18–0.91). Patients who took aspirin for ≤2 years had significantly higher risk of GIB (sHR: 1.73, 95% CI 1.07–2.79) than those not receiving aspirin. The risk of GIB started declining with the longer use of aspirin and becoming insignificant for ≥5 years’ use (sHR: 0.79, 95% CI 0.19–3.21).

DISCUSSION: Long-term aspirin use is associated with a lower risk of HCC in a duration-dependent manner in NA-treated CHB patients without a significant increase in the risk of gastrointestinal adverse effects.

SUPPLEMENTARY MATERIAL accompanies this paper at http://links.lww.com/CTG/A535; http://links.lww.com/CTG/A536; http://links.lww.com/CTG/A537; http://links.lww.com/CTG/A538; http://links.lww.com/CTG/A539.

INTRODUCTION

Hepatocellular carcinoma (HCC) is the second leading cause of cancer death worldwide (1,2). More than 500,000 new cases of HCC are diagnosed annually (2). Hepatitis B virus (HBV) infection is a crucial risk factor for HCC, and chronic hepatitis B (CHB)-related HCC is prevalent in Asia because of the endemicity of this chronic viral infection (3). Although antiviral treatment with oral nucleos(t)ide analogs (NAs) (4–6) effectively inhibits the replication of HBV, the risk of HCC is not completely abolished (7). Therefore, using NA alone may not suffice to prevent HCC, and hence, other effective strategies of chemoprophylaxis for HCC is warranted. Most studies such as a recent article by Simon et al. reported that the use of low-dose aspirin was associated with a significantly lower risk of HCC and liver-related mortality than no use of aspirin. However, to date, the chemopreventive effect of aspirin use on HCC remains controversial (8–10). For example, a 11-year follow-up of a US randomized control trial claimed no beneficial
effects from aspirin use on various cancers (11). Different study designs with limited sample size or variable follow-up durations may account for such conflicting results. Most studies were conducted in Western countries; whether aspirin works as well in Asia where HBV is highly prevalent and the main cause of HCC remains unclear. Furthermore, patients at risk of HCC should be treated with antiviral therapy, and therefore, additional chemopreventive strategy on top may further reduce the risk of HCC in NA-treated CHB patients (4–6,12). In this study, we aimed to investigate the impact of aspirin on HCC risk in patients treated with first-line NAs (entecavir, tenofovir disoproxil fumarate, and/or tenofovir alafenamide). We also reported the gastrointestinal (GI) safety of aspirin use.

METHODS

Study design and data source

A territorywide retrospective cohort study was performed by retrieving data from the Clinical Data Analysis and Reporting System (CDARS) of the Hospital Authority, Hong Kong. CDARS facilitates the retrieval of clinical data captured from different operational systems for analysis and reporting and provides high-quality information to support clinical and management decisions by integrating the clinical data resided in data warehouse (13). The electronic healthcare database includes in-patient and out-patient data from all public healthcare services in Hong Kong, which covers approximately 80% of the local population. All clinical information captured in CDARS, including patients’ demographics, diagnoses, laboratory results, and use of medications, was anonymized to ensure confidentiality.

Subjects

We evaluated adults aged 18 years or older in Hong Kong with CHB who began taking first-line NAs between September 1, 2005, and December 31, 2018 (see Supplementary Table 1, Supplementary Digital Content 1, http://links.lww.com/CTG/A535). We excluded patients coinfected with hepatitis C virus or hepatitis D virus based on International Classification of Disease, Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis codes and/or virological assays;coinfected with HIV based on ICD-9-CM diagnosis codes; had other autoimmune or metabolic liver diseases; and had HCC or liver transplant before or within 180 days from the baseline date. Patients were followed until diagnosis of HCC, censored at death, or the last follow-up date (February 29, 2020). The cohort was divided according to antiplatelet therapy (aspirin group vs no aspirin group). To ensure a new user design, the aspirin group included patients who initiated aspirin for at least 90 days during NA treatment, and the date of their first filled prescription of aspirin (the index date) was after the date of their first filled prescription of NA. The no aspirin group included patients who had never initiated any antiplatelet therapy till their last follow-up date.

Data collection

Data were retrieved from CDARS in March 2020. We defined the baseline date as the first filled prescription of aspirin in the aspirin group and a random index date in the no aspirin group, respectively. Demographics data including sex and date of birth were captured. Hematological and virological parameters, liver and renal biochemistries, relevant diagnoses and procedures, concomitant drugs, and other laboratory parameters were collected at baseline and during follow-up.

Definitions of clinical events and comorbid conditions

We defined HCC based on diagnosis codes (155.0—hepatocellular carcinoma and 155.2—carcinoma of liver) or any HCC treatment (see Supplementary Table 2, Supplementary Digital Content 2, http://links.lww.com/CTG/A536). Gastrointestinal bleeding (GIB) was defined based on diagnosis codes. Cirrhosis was defined based on the ICD-9-CM diagnosis code for cirrhosis (571/571.2/571.5/571.51/571.52/571.53) (see Supplementary Table 2, Supplementary Digital Content 2, http://links.lww.com/CTG/A536). Hypertension was identified by use of any antihypertensive drugs or ICD-9-CM diagnosis codes for hypertension (401–404) (see Supplementary Table 2, Supplementary Digital Content 2, http://links.lww.com/CTG/A536). Diabetes mellitus was classified by exposure to antidiabetic agents, and/or HbA1c ≥ 6.5%, and/or fasting plasma glucose ≥ 7 mmol/L in 2 measurements or ≥ 11.1 mmol/L in 1 measurement, and/or the ICD-9-CM diagnosis codes for diabetes mellitus (250–250.93) (see Supplementary Table 2, Supplementary Digital Content 2, http://links.lww.com/CTG/A536).

Clinical outcomes

The primary outcome was incident HCC; secondary outcome was incident GIB as the safety endpoint. Competing events were death and liver transplantation for analysis of HCC and death for analysis of GIB.

Statistical analysis

Data were analyzed using Statistical Product and Service Solutions (SPSS) Statistics for Windows, version 25.0 (IBM, Armonk, NY), SAS (9.4; SAS Institute, Cary, NC), and R software (4.0.0; R Foundation for Statistical Computing, Vienna, Austria). Continuous variables were expressed as mean ± SD or median (interquartile range [IQR]), as appropriate, while categorical variables were presented as number (percentage). Qualitative and quantitative differences between subgroups were analyzed by χ² or Fisher exact tests for categorical parameters and the Student t test or the Mann-Whitney test for continuous parameters, as appropriate. Cumulative incidence function of HCC with adjustment of competing risk of death and liver transplantation was estimated with 95% confidence interval (CI). We used the Gray test to assess differences between the cohorts.

Inappropriate missing data handling would lead to a faulty conclusion by reducing the statistical power of a study and/or creating biased estimates because of selection bias. Random forest-based multivariate imputation by chained equations was performed to minimize imputation error for both continuous and categorical variables (14). The imputed variables (missing percentage) were platelet counts (3.69%), creatinine (4.3%), albumin (2.42%), total bilirubin (2.45%), alanine aminotransferase (ALT) (2.4%), and hepatitis B e antigen status (27.95%). These covariates, together with 12 important baseline characteristics, the event indicator, and Nelson-Aalen estimator of the cumulative hazard at the time of event or censoring, were included in the imputation model.

For multivariable analyzes, hazard ratios (HRs) and 95% CIs for HCC and GIB were estimated using Fine and Gray competing risks regression model, again accounting for competing risks (15). The overall coefficient estimates and SEs were computed by combining the estimates obtained in each individual multiple imputation data set using Rubin rules.
Table 1. Clinical characteristics of patients with chronic hepatitis B according to aspirin use

| Clinical characteristics | No aspirin use (N = 33,367) | Aspirin use* (N = 1,744) | P valueb |
|-------------------------|-------------------------------|---------------------------|----------|
| Age (yr)c,d | 52.5 (12.5) | 62.2 (10.8) | <0.001 |
| Male sex, n(%)c,d | 20,414 (61.2) | 2,103 (69.0) | <0.001 |
| Cirrhosis, n(%)c,d,g | 2,177 (61.7) | 197 (11.3) | <0.001 |
| Hypertension, n(%)c,d,g | 7,410 (22.2) | 1,105 (63.4) | <0.001 |
| Renal replacement therapy, n(%)c,d | 132 (0.4) | 58 (3.3) | <0.001 |
| Diabetes mellitus, n(%)c,d,g | 5,729 (17.2) | 662 (38.0) | <0.001 |
| Platelet (x10^9/L)c,d | 191.5 (69.9) | 191.2 (92.4) | 0.89 |
| Creatinine (μmol/L)c,d | 76.0 (64.0–89.0) | 82.0 (69.2–99.3) | <0.001 |
| Albumin (g/L)c,d | 41.6 (5.0) | 39.9 (6.0) | <0.001 |
| Total bilirubin (μmol/L)c,d | 14.1 (17.2) | 13.5 (10.5) | 0.02 |
| Alanine aminotransferase (IU/L)c,d | 29.0 (20.0–48.0) | 24.0 (17.0–35.0) | <0.001 |
| Positive HBeAgc,d,g | 4,770 (18.2) | 156 (10.3) | <0.001 |
| HbA1c (%)c,d | 6.4 (3.0) | 7.0 (5.1) | <0.001 |
| Time-weighted average HbA1c (%) | 12.9 (8.8) | 14.3 (9.4) | <0.001 |
| Fasting glucose (mmol/L) | 5.7 (1.6) | 6.3 (2.3) | <0.001 |
| Triglycerides (mmol/L) | 1.2 (0.8) | 1.3 (0.9) | <0.001 |
| Total cholesterol (mmol/L) | 4.8 (1.0) | 4.6 (1.1) | <0.001 |
| LDL-cholesterol (mmol/L) | 2.8 (0.8) | 2.7 (0.9) | <0.001 |
| HDL-cholesterol (mmol/L) | 1.4 (0.4) | 1.3 (0.4) | <0.001 |
| Follow-up duration (yr) | 3.3 (2.0–6.1) | 2.8 (1.5–4.9) | <0.001 |
| Possible reasons for the use of aspirin therapy, n (%) | 12,080 (36.2) | 1,589 (91.1) | <0.001 |
| Risk factors of cardiovascular disease, n(%)h | 11,538 (34.6) | 1,527 (87.6) | <0.001 |
| Stroke, n (%) | 487 (1.5) | 338 (19.4) | <0.001 |
| Ischemic heart disease, n (%) | 48 (0.1) | 278 (15.9) | <0.001 |
| Cardiac dysrhythmias and heart failure, n (%) | 977 (2.9) | 311 (17.8) | <0.001 |
| Operations on vessels of heart, n (%)) | 6 (0.02) | 169 (9.7) | <0.001 |
| Any use of antiviral therapy, n(%)h,i | 33,367 (100.0) | 1,744 (100.0) | <0.001 |
| Nucleos(t)ide analogs | 28,041 (84.0) | 1,508 (86.5) | 0.006 |
| Entecavir | 3,402 (10.2) | 131 (7.5) | <0.001 |

Table 1. (continued)

| Clinical characteristics | No aspirin use (N = 33,367) | Aspirin use* (N = 1,744) | P valueb |
|-------------------------|-------------------------------|---------------------------|----------|
| Nucleos(t)ide analogs | 33,367 (100.0) | 1,744 (100.0) | <0.001 |
| Entecavir | 28,041 (84.0) | 1,508 (86.5) | 0.006 |
| Tenofovir disoproxil fumarate | 3,402 (10.2) | 131 (7.5) | <0.001 |

Differences in baseline comorbidities and the usage of medications associated with HCC were observed between the 2 groups (Table 1), and there were potential confounding variables associated with HCC present. Therefore, we developed propensity score (PS), the conditional probability of initiating aspirin, to control for these confounders (16,17). Seventeen important baseline characteristics selected priori were incorporated into the PS model as shown in Table 1. These baseline variables were balanced in the PS model to minimize indication bias and any resultant confounding effects on the HCC and GIB. The balance of covariates by PS was assessed by 2 summary statistics: the absolute standardized mean difference (ASMD) and the Kolmogorov-Smirnov statistic (KS). Both mean and maximum of either ASMD or KS were the 4 stopping rules for assessing the covariate balance between the aspirin group and no aspirin group (i.e., ASMD >0.2 and/or KS >0.1 as an indication of imbalance) (18–20). PS matching with a nearest-neighbors matching with a caliper width of 0.2 SD was used to create matched samples.
neighbor 1:3 matching scheme with the logit of the PS within 0.1 SD was used were used to balance the clinical characteristics. The relationship between duration of aspirin use and outcomes was evaluated using time-varying aspirin exposures. To assess drug duration, the duration of aspirin for a specific patient was calculated by the sum of the days with filled prescription of aspirin of that user. We counted the days with aspirin prescribed only to achieve high accuracy and updated these data at each new prescription time interval of follow-up.

RESULTS
Patient characteristics
We identified 55,119 CHB patients who received entecavir, tenofovir disoproxil fumarate, and/or tenofovir alafenamide treatment. We excluded 744 patients with coinfections with hepatitis C virus, hepatitis D virus, and HIV; 36 patients with other autoimmune or metabolic liver diseases; 6,464 patients who had incident HCC less than 180 days from baseline date; 241 patients who had liver transplant less than 180 days from baseline; 571 patients who died less than 180 days from baseline; and 122 patients who had history of HCC less than 180 days from baseline. To avoid immortal time bias, 5,683 patients with follow-up of less than 180 days were not included in this study. Furthermore, we excluded 5,555 patients who initiated aspirin earlier than NAs, 187 nonaspirin users who had received other antiplatelet therapy, and 405 aspirin users whose cumulative prescription duration of aspirin was <90 days during follow-up to ensure aspirin efficacy in preventing HCC. In the final analysis, 35,111 patients were included in the study cohorts (Figure 1, 1,744 aspirin group and 33,367 no aspirin group). All study patients were taking aspirin for prevention of cardiovascular and cerebrovascular diseases; no patients took aspirin for HCC prevention. More than 90% of our study participants had high risk of CVD or stroke events while less than 10% of the subjects may had the risk of colorectal cancer and adenomas (Table 1).

The mean age was 53.0 years, and 61.6% were men. One thousand two hundred three (69.0%) male patients belonged to the aspirin group, whereas 20,414 (61.2%) men were in the no aspirin group. Sixty-nine (4.0%) and 1,488 (4.5%) patients developed HCC at median (IQR) of 2.72 (1.44–4.81) years and 3.23 (1.79–6.01) years in the aspirin group and no aspirin group, respectively. The median (IQR) duration of aspirin prescription was 2.84 (1.57–4.86) years. After a 1:3 PS matching, the total sample size was 6,222 (Table 2, 1,711 aspirin group and 4,511 no aspirin group). The PS-matched cohort was composed of the mean age of 61.9 years and 65.8% men. The median (IQR) of duration of aspirin prescription was changed to 2.57 (1.25–4.62) years.

Hepatocellular carcinoma
In the univariate analysis, the 5-year cumulative incidence of HCC was 3.33% (95% CI 2.48–4.17) in the aspirin group and 3.52% (95% CI 3.32–3.72) in the no aspirin group (difference: −0.2%, 95% CI −0.45% to 0.05%; P = 0.695) (Table 3 and Figure 2). In the multivariable model, the aspirin group had a 40% lower risk of HCC than the no aspirin group after adjusting all covariates (adjusted multivariable model subhazard ratio [sHR], 0.60, 95% CI 0.46–0.78; P < 0.001) (see Supplementary Table 3, Supplementary Digital Content 3, http://links.lww.com/CTG/A537). The results were similar after PS matching for the 2 cohorts (PS-matched sHR, 0.66, 95% CI 0.49–0.87; P = 0.004).

Duration of aspirin use in risk of HCC
An inverse relationship between duration of aspirin and the risk of HCC was observed. The duration-dependent association was significant with the use of aspirin longer than 3 months (adjusted sHR from 3 months up to 2 years, 0.65, 95% CI 0.47–0.92) (Table 4). The longer the duration of aspirin had been initiated, the lower the risk of HCC found. The risk of HCC in groups of 2- to 5-year aspirin use and more than 5-year aspirin use were 37% (adjusted sHR from 2 years up to 5 years, 0.63, 95% CI 0.43–0.94) and 59% (adjusted sHR from more than 5 years, 0.41, 95% CI 0.18–0.91) lower than that of the no aspirin group.

Safety of aspirin user in CHB patient: incident GIB
In the univariate analysis, the 5-year cumulative incidence of GIB was 1.78% (95% CI 1.14–2.41) among the aspirin group

Figure 1. Selection of patients with chronic hepatitis B (CHB) prescribed with first-line oral nucleos(t)ide analogs (ETV and/or TDF). ETV, entecavir; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; HDV, hepatitis D virus; TDF, tenofovir disoproxil fumarate.
and 0.75% (95% CI 0.66–0.85) among the no aspirin group (difference: 1.03%, 95% CI 0.89%–1.43%; \( P < 0.001 \)) (Table 3 and Figure 2). The risk of GIB was not significant in the aspirin group after adjusting all covariates (adjusted multivariable model sHR, 1.11, 95% CI 0.87–1.42; \( P = 0.391 \)) (see Supplementary Table 4, Supplementary Digital Content 4, http://links.lww.com/CTG/A538). The results were similar after PS-matching analysis (PS-matched sHR, 1.41, 95% CI 1.07–1.79; \( P = 0.026 \)). However, the risk of GIB started declining with the longer use of aspirin. The adjusted sHR (from 2 years up to 5 years) was 1.19 (95% CI 0.96–1.79; \( P = 0.026 \)) decreased to 0.79 (more than 5 years, 95% CI 0.19–3.21; \( P = 0.737 \)).

### Table 2. Comparison of baseline characteristics before and after propensity score weighting (first imputation)

| Clinical characteristics | Unadjusted | Unadjusted | ASMD | Unadjusted | Unadjusted | ASMD |
|--------------------------|------------|------------|------|------------|------------|------|
| Age (yr)                 | 62.2 (10.8) | 52.5 (12.5) | 0.9  | 62.1 (10.8) | 62.1 (10.8) | 0.03 |
| Male sex                 | 1,203 (69.0)| 20,414 (61.2)| 0.17 | 1,175 (68.7)| 2,918 (64.7)| 0.08 |
| Cirrhosis                | 197 (11.3)  | 2,177 (6.5)  | 0.15 | 189 (11.0)  | 442 (9.8)   | 0.04 |
| Hypertension             | 1,105 (63.4)| 7,410 (22.2)| 0.85 | 1,073 (62.7)| 2,753 (61.0)| 0.04 |
| Renal replacement therapy| 58 (3.3)    | 132 (0.4)    |      | 47 (2.7)    | 64 (1.4)    | 0.10 |
| Diabetes                 | 662 (38.0)  | 5,729 (17.2) | 0.43 | 641 (37.5)  | 1,857 (41.2)| 0.09 |
| Platelet (\( \times 10^9/L \)) | 191.2 (92.4)| 191.5 (69.9) | 0    | 189.0 (79.4)| 188.2 (73.9)| 0.01 |
| Creatinine (\( \mu \text{mol/L} \)) | 118.2 (158.3)| 80.7 (49.0)  | 0.24 | 81.8 (69.0–98.0)| 81.0 (68.0–96.0)| 0.08 |
| Albumin (g/L)            | 39.9 (6.0)  | 41.6 (5.0)   | 0.28 | 40.1 (5.9)  | 40.5 (5.6)  | 0.09 |
| Total bilirubin (\( \mu \text{mol/L} \)) | 13.5 (10.5) | 14.1 (17.2)  | 0.06 | 13.6 (10.5) | 13.5 (11.9) | 0.01 |
| Alanine aminotransferase (IU/L) | 24.0 (17.0–35.0) | 29.0 (20.0–48.0) | 0.45 | 24.0 (17.0–35.0) | 25.0 (18.0–36.0) | 0.06 |
| Positive HBeAg           | 156 (10.3)  | 4,770 (18.2) | 0.22 | 151 (10.1)  | 399 (10.8)  | 0.01 |
| HbA1c (%)                | 7.0 (5.1)   | 6.4 (3.0)    |      | 7.0 (5.1)   | 6.8 (3.8)   |      |
| Fast glucose (mmol/L)    | 6.3 (2.3)   | 5.7 (1.6)    |      | 6.3 (2.3)   | 6.2 (1.9)   |      |
| Triglycerides (mmol/L)   | 1.3 (0.9)   | 1.2 (0.8)    |      | 1.3 (0.9)   | 1.3 (0.8)   |      |
| Total cholesterol (mmol/L) | 4.6 (1.1)   | 4.8 (1.0)    |      | 4.6 (1.1)   | 4.7 (1.1)   |      |
| LDL-cholesterol (mmol/L) | 2.7 (0.9)   | 2.8 (0.8)    |      | 2.7 (0.9)   | 2.8 (0.9)   |      |
| HDL-cholesterol (mmol/L) | 1.3 (0.4)   | 1.4 (0.4)    |      | 1.3 (0.4)   | 1.4 (0.4)   |      |
| Follow-up duration (yr)  | 2.8 (1.5–4.9)| 3.3 (2.0–6.1)| 0.22 | 2.82 (1.5–5.0)| 3.1 (1.5–5.3)|      |
| Any use of antiviral therapy | 1,744 (100.0) | 33,367 (100.0) | 0.34 | 1,711 (100.0) | 4,511 (100.0) | 0.09 |
| Nucleos(t)ide analogs    | 1,508 (86.5)| 28,041 (84.0)| 0.45 | 1,477 (86.3)| 4,032 (89.4)| 0.02 |
| TDF                      | 131 (7.5)   | 3,402 (10.2) | 0.28 | 130 (7.6)   | 303 (6.7)   | 0.07 |
| ETV + TDF                | 105 (6.0)   | 1,924 (5.8)  | 0.61 | 104 (6.1)   | 176 (3.9)   | 0.07 |
| (Pegylated)-interferon    | 32 (1.8)    | 530 (1.6)    |      | 32 (1.9)    | 29 (0.6)    |      |
| Any use of concomitant drugs | 467 (26.8) | 3,873 (11.6) | 0.34 | 454 (26.5) | 1,369 (30.3) | 0.09 |
| Metformin                | 464 (26.6)  | 3,924 (11.8) | 0.34 | 448 (26.2)  | 1,324 (29.4) | 0.07 |
| Sulphonylureas           | 348 (20.0)  | 2,493 (7.5)  | 0.31 | 330 (19.3)  | 804 (17.8)  | 0.02 |
| Insulin                  | 1,182 (67.8)| 5,307 (15.9) | 0.11 | 1,153 (67.4)| 3,061 (67.9)| 0.01 |
| ACEIs/ARBs               | 771 (44.2)  | 4,640 (13.9) | 0.61 | 741 (43.3)  | 1,930 (42.8)| 0.02 |
| NSAIDs                   | 879 (50.4)  | 13,412 (40.2)| 0.2  | 860 (50.3)  | 2,240 (49.7)| 0.05 |

Data are shown as mean (SD) or median (interquartile range) or n (%).

ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; ASMD, absolute standardized mean difference; ETV, entecavir; HBeAg, hepatitis B e antigen; HDL, high-density lipoprotein; LDL, low-density lipoprotein; NSAID, nonsteroidal anti-inflammatory drug; PS, propensity score; TDF, tenofovir disoproxil fumarate.

Duration of aspirin use in risk of GIB

In general, there was a higher risk of GIB in the aspirin group (adjusted sHR ranged from 0.79 to 1.73) (Table 4). The risk was significantly higher with use of aspirin from 3 months up to 2 years’ use than no use (adjusted sHR from 3 months up to 2 years, 1.73, 95% CI 1.07–2.79; \( P = 0.026 \)). However, the risk of GIB started declining with the longer use of aspirin. The adjusted sHR (from 2 years up to 5 years) was 1.19 (95% CI 0.60–2.35; \( P = 0.624 \)) decreased to 0.79 (more than 5 years, 95% CI 0.19–3.21; \( P = 0.737 \)).
DISCUSSION

We report the chemoprophylactic effect of aspirin on HCC in NA-treated CHB patients in this territorywide, retrospective cohort study. Aspirin use for 5 years or longer was associated with as much as a 40% risk reduction of HCC. A duration-dependent association was significant with the use of aspirin longer than 3 months, which provided at least 35% risk reduction of HCC. In other words, the longer the duration of aspirin had been initiated, the lower the risk of HCC found. The risk of GIB was not significant in long-term aspirin users for 5 years or more; instead, the risk was significantly higher in short-term aspirin users for 3 months to 2 years compared with nonusers.

There has been evolving evidence supporting aspirin to reduce HCC risk in NA-treated CHB patients. Continuing aspirin therapy was recommended by the American Heart Association/American College of Cardiology and American Stroke Association practice guidelines. Therefore, we anticipated that most of our study participants were regular aspirin users (see Supplementary Table 5, Supplementary Digital Content 4, http://links.lww.com/CTG/A539). The high medication possession ratio (the duration of aspirin divided by the duration of follow-up) reflected that a majority of aspirin users in this cohort had their therapy on a regular basis (see Supplementary Table 4, Supplementary Digital Content 4, http://links.lww.com/CTG/A538). Our PS-matched cohort had shown a 34% risk reduction of HCC, similar to another prospective US cohort study which indicated that regular aspirin use was associated with significantly lower HCC risk compared with non-regular use (multivariable HR 0.51, 95% CI 0.34–0.77) (8). A Taiwanese nationwide cohort study also illustrated daily aspirin use for 3 months to 2 years compared with nonusers. There has been evolving evidence supporting aspirin to reduce HCC risk in NA-treated CHB patients. Continuing aspirin therapy was recommended by the American Heart Association/American College of Cardiology and American Stroke Association practice guidelines. Therefore, we anticipated that most of our study participants were regular aspirin users (see Supplementary Table 5, Supplementary Digital Content 4, http://links.lww.com/CTG/A539). The high medication possession ratio (the duration of aspirin divided by the duration of follow-up) reflected that a majority of aspirin users in this cohort had their therapy on a regular basis (see Supplementary Table 4, Supplementary Digital Content 4, http://links.lww.com/CTG/A538). Our PS-matched cohort had shown a 34% risk reduction of HCC, similar to another prospective US cohort study which indicated that regular aspirin use was associated with significantly lower HCC risk compared with non-regular use (multivariable HR 0.51, 95% CI 0.34–0.77) (8). A Taiwanese nationwide cohort study also illustrated daily aspirin therapy had a reduced incidence of HCC in patients with CHB, regardless of whether their antiviral treatment has ever initiated (21). In addition, the effectiveness of aspirin in HCC prevention was confirmed by a recent meta-analysis which was composed of 8 studies with 2,604,319 participants (HR 0.59, 95% CI 0.47–0.75) (22). Furthermore, the prolonged latency effect of aspirin is demonstrated in our study. HCC risk in the aspirin group, with more than 5 years’ use, was 59% lower than the no aspirin group. A nationwide Swedish research study reported a similar finding, in which aspirin use more than 5 years would halve the risk of HCC (multivariable HR 0.57, 95% CI 0.42–0.70) (8). The chemoprophylactic effect of long-term aspirin use on HCC was also verified by another Chinese cohort (10); the risk of developing HCC was reduced by 51% among aspirin users compared with nonusers in mean aspirin duration of 7.7 years (relative risk 0.49).

Several preclinical studies support the function of aspirin in the prevention of HCC by diminishing immune-mediated necroinflammatory reactions, the severity of liver fibrosis or the stage of HCC (11). Inflammation-related cancers such as HCC overexpress the proinflammatory cyclooxygenase-2 (COX-2) enzyme which activates profibrotic and proliferative signaling cascades. Aspirin facilitates selective COX-2 inhibition, which reduces liver fibrosis, portal hypertension, and proliferation of liver cancer cells. All these mechanistic effects contribute to the chemoprophylactic effect of aspirin for HCC (8,23).

GI safety is an imperative concern in long-term antiplatelet therapy. GIB or upper GI upset is mainly contributed by COX-2 inhibition, which protects the delicate lining of the stomach (24,25) and thus makes aspirin as an important risk factor for GIB. In this study, aspirin was not associated with risk of GIB in a 5-year follow-up with adjustment of nonsteroidal anti-inflammatory drug use. Comparable cohorts in Taiwan also reported that GIB events were not significant among the aspirin users as monotherapy. Interestingly, aspirin use for longer duration was as not related to corresponding higher risk of GIB than no aspirin use. The counterintuitive findings were also reported by Simon et al. (8) and Huang et al. (26). Huang et al. concluded that risk of GIB was strongly related to the daily dose rather than duration of aspirin use, such that increasing duration of use did not confer a greater risk of bleeding after adjusting all confounding variables. It was postulated that long-term aspirin use is associated with mucosal adaptations that protect against bleeding events (27). Long-term aspirin use may result in enhancing mucosal expression of nitric oxide synthase and upregulating mucosal cell growth, and thus, a smaller risk estimate is expected (26). Although the mentioned findings are encouraging, practitioners should still be aware of the negative consequence of assigning short-term aspirin therapy as it has significant relationship with GIB risk (Adjusted sHR from 3 months up to 2 years, 1.73, 95% CI 1.07–2.79).

**Table 3. Effect of aspirin use on risk of incident hepatocellular carcinoma (HCC) and gastrointestinal bleeding (GIB).**

| Event and treatment group | No. with event/total no. | 5-yr cumulative incidence | Hazard ratio (95% confidence interval) |
|---------------------------|--------------------------|---------------------------|---------------------------------------|
|                           |                          |              | Unadjusted | Adjusted (multivariable model) | Propensity score–matched |
| **Incident HCC**          |                          |              |            |                            |                          |
| No aspirin use            | 1,488/33,367             | 3.33%        | 1.04 (0.80–1.36), P = 0.763 | 0.60 (0.46–0.78), P <0.001 | 0.66 (0.49–0.87), P = 0.004 |
| Aspirin use               | 69/1,744                 | 3.52%        | 1.13 (0.89–1.43), P = 0.331 | 1.11 (0.87–1.42), P = 0.391 | 1.41 (0.96–2.08), P = 0.082 |
| Absolute risk difference (95%) |          |            | ++0.2% (−0.45% to 0.05%) |                                |                          |
| **GIB**                   |                          |              |            |                            |                          |
| No aspirin use            | 313/32,763               | 0.75%        | 1.11 (0.87–1.42), P = 0.391 | 1.41 (0.96–2.08), P = 0.082 |                          |
| Aspirin use               | 32/1,684                 | 1.78%        | 1.13 (0.89–1.43), P = 0.331 | 1.11 (0.87–1.42), P = 0.391 | 1.41 (0.96–2.08), P = 0.082 |
| Absolute risk difference (95%) |          |            | 1.03% (0.88% to 1.18%) |                                |                          |
Aspirin therapy primarily as chemoprophylaxis in CHB patients is not yet a common practice in Hong Kong, which makes the current study an advantage (10). Owning to the fact that most of alike studies were mainly conducted in Western countries, for instance, the United States, those researches would often have difficulty in defining prescription duration of aspirin. Aspirin is an over-the-counter medication that can be easily bought in pharmacies or convenience stores outside the hospital settings thus some of the cohort studies may only able to classify subjects with no regular use of aspirin as the control group (16). As a result, the effectiveness of aspirin in preventing HCC was not clearly shown in western cohorts. Moreover, our study has the strength of huge sample size of a well-characterized NA-treated CHB patients from this territorywide database, which have led to high statistical power and robust estimators in view of large sample size, together with robust, well-validated diagnosis and procedures coding. Data from real-life cohorts represent a wider spectrum of patients than those in randomized controlled trials, which increases the applicability of our findings to routine clinical practice.

**Figure 2.** Cumulative incidence of events in the aspirin group vs no aspirin group: (a) HCC (unadjusted), (b) GIB (unadjusted), (c) HCC (PS-adjusted), and (d) GIB (PS-adjusted). CI, confidence interval; GIB, gastrointestinal bleeding; HCC, hepatocellular carcinoma; PS, propensity score.

Aspirin therapy primarily as chemoprophylaxis in CHB patients is not yet a common practice in Hong Kong, which makes the current study an advantage (10). Owning to the fact that most of alike studies were mainly conducted in Western countries, for instance, the United States, those researches would often have difficulty in defining prescription duration of aspirin. Aspirin is an over-the-counter medication that can be easily bought in pharmacies or convenience stores outside the hospital settings thus some of the cohort studies may only able to classify subjects with no regular use of aspirin as the control group (16). As a result, the effectiveness of aspirin in preventing HCC was not clearly shown in western cohorts. Moreover, our study has the strength of huge sample size of a well-characterized NA-treated CHB patients from this territorywide database, which have led to high statistical power and robust estimators in view of large sample size, together with robust, well-validated diagnosis and procedures coding. Data from real-life cohorts represent a wider spectrum of patients than those in randomized controlled trials, which increases the applicability of our findings to routine clinical practice.
We acknowledge several limitations to our study. First, missing data or incomplete data sets would lead to statistical power reduction, biased estimations, and invalid conclusions. Multiple imputation was introduced to rectify our analysis. Low imputation error and small prediction di-

| Duration of aspirin | Hazard ratio (95% confidence interval) | P     |
|--------------------|----------------------------------------|-------|
| Incident HCC       |                                        |       |
| 0 to <3 mo         | 1 (reference)                          |       |
| 3 mo to <2 yr      | 0.65 (0.47–0.92)                       | 0.014 |
| 2 yr to <5 yr      | 0.63 (0.43–0.94)                       | 0.022 |
| ≥5 yr              | 0.41 (0.18–0.91)                       | 0.03  |
| GIB                |                                        |       |
| 0 to <3 mo         | 1 (reference)                          |       |
| 3 mo to <2 yr      | 1.73 (1.07–2.79)                       | 0.026 |
| 2 yr to <5 yr      | 1.19 (0.60–2.35)                       | 0.624 |
| ≥5 yr              | 0.79 (0.19–3.21)                       | 0.737 |

In conclusion, this territorywide, retrospective cohort study showed that aspirin use is associated with a lower risk of HCC in a duration-dependent manner in NA-treated CHB patients without a significant increase in the risk of GI adverse effects. This study has provided important evidence for the practice guidelines to review the chemoprophylactic strategy in CHB patients, particularly those at risk of HCC. Aspirin therapy may provide additional benefit to NA treatment to further reduce HCC risk.

CONFLICTS OF INTEREST
Guarantor of the article: Grace Lai-Hung Wong, MD.

Specific author contributions: V.W.-K.H., T.C.-F.Y., Y.-K.T., and G.L.-H.W.: were responsible for the acquisition and analysis of data and had full take responsibility for the integrity of the data and the accuracy of the data analysis. All authors were responsible for the study concept and design for the interpretation of data, drafting, and critical revision of the article for important intellectual content.

Financial support: None to report.

Potential competing interests: V.W.-S. Wong has served as an advisory committee member for AbbVie, Allergan, Echosens, Gilead Sciences, Janssen, Perspectum Diagnostics, Pfizer, and Terns and a speaker for Bristol-Myers Squibb, Echosens, Gilead Sciences and Merck. T.C.-F. Yip has served as a speaker and an advisory committee member for Gilead Sciences. H.L.-Y. Chan has served as an advisory committee member for AbbVie, Aptomum, Altimmune, Arbutus, ContraVir, Intellia, Janssen, Gilead, MedImmune, Roche, Vir Biotechnology, GRAIL, and Vaccitech and as a speaker for AbbVie, Gilead, and Roche. G.C.-Y. Lui has served as an advisory committee member for Gilead, Merck, and GSK, speaker for Merck and Gilead, and received research grant from Gilead, Merck, and GSK. G.L.-H. Wong has served as an advisory committee member for Gilead Sciences and Janssen, as a speaker for Abbott, AbbVie, Bristol-Myers Squibb, Echosens, Furui, Gilead Sciences, Janssen, and Roche and received research grant from Gilead Sciences. The other authors declare that they have no competing interests.

Study Highlights

WHAT IS KNOWN

✓ Aspirin therapy may provide additional chemopreventive benefit on top of treatment to further reduce hepatocellular carcinoma risk.

WHAT IS NEW HERE

✓ Long-term aspirin use is associated with a lower risk of hepatocellular carcinoma in a duration-dependent manner in nucleos(t)ide analog-treated chronic hepatitis B patients, without a significant increase in the risk of gastrointestinal (GI) adverse effects

✓ Patients who took shorter duration of aspirin for ≤2 years had significantly higher risk of GI bleeding than those not receiving aspirin. The risk of GI bleeding started declining with the longer use of aspirin and becoming insignificant for ≥5 years’ use.

TRANSLATIONAL IMPACT

✓ Long-term aspirin use is associated with a lower risk of HCC in a duration-dependent manner in NA-treated CHB patients without a significant increase in the risk of gastrointestinal adverse effects.

REFERENCES

1. Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin 2015;65(2):87–108.
2. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136(5):E359–86.
3. Chan SL, Wong V, Qin S, et al. Infection and cancer: The case of hepatitis B. J Clin Oncol 2016;34(1):83–90.
4. Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: A 2015 update. Hepatol Int 2016;10(1):1–98.
5. Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology 2018;67(4):1560–99.
6. European Association for the Study of the Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012;57(1):167–85.
7. Wu CY, Lin JT, Ho HJ, et al. Association of nucleos (t) ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B—A nationwide cohort study. Gastroenterology 2014;147(1):143–51.e5.
8. Simon TG, Ma Y, Ludvigsson JF, et al. Association between aspirin use and risk of hepatocellular carcinoma. JAMA Oncol 2018;4(12):1683–90.
9. Simon TG, Duberg AS, Aleman S, et al. Association of aspirin with hepatocellular carcinoma and liver-related mortality. N Engl J Med 2020;382(11):1018–28.
10. Tsoi KK, Ho JM, Chan FC, et al. Long-term use of low-dose aspirin for cancer prevention: A 10-year population cohort study in Hong Kong. Int J Cancer 2019;145(1):267–73.
11. Flossmann E, Rothwell PM. Effect of aspirin on long-term risk of colorectal cancer: Consistent evidence from randomised and observational studies. Lancet 2007;369(9573):1603–13.
12. Hui VWK, Chan SL, Wong VWS, et al. Increasing antiviral treatment uptake improves survival in patients with HBV-related hepatocellular carcinoma. JHEP Rep 2020;2(6):100152.
13. Yip TCF, Wong VWS, Chan HLY, et al. Tenofovir is associated with lower risk of hepatocellular carcinoma than entecavir in patients with chronic HBV infection in China. Gastroenterology 2020;158(1):215–25.e6.
14. Waljee AK, Mukherjee A, Singal AG, et al. Comparison of imputation methods for missing laboratory data in medicine. BMJ Open 2013;3(8):e002847.
15. White IR, Royston P. Imputing missing covariate values for the Cox model. Stat Med 2009;28(15):1982–98.
16. Braitman LE, Rosenbaum PR. Rare outcomes, common treatments: Analytic strategies using propensity scores. Ann Intern Med 2002;137(8):693–5.
17. Glynn RJ, Schneeweiss S, Sturmer T. Indications for propensity score methods in comparative effectiveness research. J Clin Epidemiol 2013;66(8):584–90.
18. McCaffrey DF, Griffin BA, Almirall D, et al. A tutorial on propensity score estimation for multiple treatments using generalized boosted models. Stat Med 2013;32(19):3388–414.
19. Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med 2009;28(25):3083–107.
20. Lee TY, Hsu YC, Tseng HC, et al. Association of daily aspirin therapy with risk of hepatocellular carcinoma in patients with chronic hepatitis B. JAMA Intern Med 2019;179(5):633–40.
21. Wang S, Yu Y, Ryan PM, et al. Association of aspirin therapy with risk of hepatocellular carcinoma: A systematic review and dose-response analysis of cohort studies with 2.5 million participants. Pharmacol Res 2020;151:104585.
22. Roehlen N, Baumert TF. Uncovering the mechanism of action of aspirin in HCC chemoprevention. EBioMedicine 2019;46:21–2.
23. Chan FKL, Goh KL, Reddy N, et al. Management of patients on antithrombotic agents undergoing emergency and elective endoscopy: Joint Asian Pacific Association of Gastroenterology (APAGE) and Asian Pacific Society for Digestive Endoscopy (APSDE) practice guidelines. Gut 2018;67(3):405–17.
24. Lee TY, Hsu YC, Tseng HC, et al. Association of daily aspirin therapy with risk of hepatocellular carcinoma in patients with chronic hepatitis B. JAMA Intern Med 2019;179(5):633–40.